Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
36
CORT Quote, Financials, Valuation and Earnings
Last price:
$34.18
Seasonality move
:
8.39%
Day range:
$28.66 - $40.28
52-week range:
$28.66 - $117.33
Dividend yield:
0%
P/E ratio:
39.12x
P/S ratio:
5.52x
P/B ratio:
5.70x
Volume:
11.8M
Avg. volume:
2.1M
1-year change:
-53.43%
Market cap:
$3.6B
Revenue:
$675M
EPS (TTM):
$0.88
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CORT
Corcept Therapeutics, Inc.
|
$254.9M | $0.33 | 27.74% | -71.78% | $84.00 |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$807.3M | $0.18 | 6.58% | 416.62% | $15.20 |
|
AXSM
Axsome Therapeutics, Inc.
|
$193.3M | -$0.73 | 58.1% | -49.24% | $216.09 |
|
HROW
Harrow, Inc.
|
$88.4M | $0.48 | 43.33% | 150.93% | $70.63 |
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$201.9M | -$1.17 | 19.04% | -14.86% | $56.55 |
|
UTHR
United Therapeutics Corp.
|
$811.4M | $7.24 | 3.2% | 9.77% | $531.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CORT
Corcept Therapeutics, Inc.
|
$34.24 | $84.00 | $3.6B | 39.12x | $0.00 | 0% | 5.52x |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$14.60 | $15.20 | $4.6B | 1,035.46x | $0.00 | 0% | 1.59x |
|
AXSM
Axsome Therapeutics, Inc.
|
$186.18 | $216.09 | $9.4B | -- | $0.00 | 0% | 16.33x |
|
HROW
Harrow, Inc.
|
$50.82 | $70.63 | $1.9B | -- | $0.00 | 0% | 7.59x |
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$21.83 | $56.55 | $2.1B | -- | $0.00 | 0% | 3.20x |
|
UTHR
United Therapeutics Corp.
|
$476.05 | $531.25 | $20.5B | 18.04x | $0.00 | 0% | 7.34x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.733 | 0.07% | 2.85x |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
104.25% | 0.556 | 83.58% | 1.31x |
|
AXSM
Axsome Therapeutics, Inc.
|
74.78% | -0.322 | 3.58% | 1.45x |
|
HROW
Harrow, Inc.
|
84.27% | 1.748 | 14.12% | 2.34x |
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
106.83% | 0.914 | 56.24% | 2.22x |
|
UTHR
United Therapeutics Corp.
|
-- | 1.177 | -- | 5.61x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$274M | $72.8M | 2.24% | -587.3% | 9.28% | $96M |
|
AXSM
Axsome Therapeutics, Inc.
|
$156.7M | -$32.9M | -82.07% | -327.97% | -19.26% | $988K |
|
HROW
Harrow, Inc.
|
$53.9M | $14.7M | -1.76% | -8.95% | 20.59% | $16.4M |
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$169.2M | -$114M | -54.16% | -558.7% | -55.07% | -$100.8M |
|
UTHR
United Therapeutics Corp.
|
$698.6M | $389.3M | 18.69% | 19.2% | 48.69% | $346.1M |
Corcept Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CORT or AMRX?
Amneal Pharmaceuticals, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 2.31%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Amneal Pharmaceuticals, Inc.'s return on equity of -587.3%.
Company Gross Margin Earnings Per Share Invested Capital CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M AMRXAmneal Pharmaceuticals, Inc.34.92% $0.01 $2.6B -
What do Analysts Say About CORT or AMRX?
Corcept Therapeutics, Inc. has a consensus price target of $84.00, signalling upside risk potential of 145.33%. On the other hand Amneal Pharmaceuticals, Inc. has an analysts' consensus of $15.20 which suggests that it could grow by 4.11%. Given that Corcept Therapeutics, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CORTCorcept Therapeutics, Inc.3 1 1 AMRXAmneal Pharmaceuticals, Inc.2 0 0 -
Is CORT or AMRX More Risky?
Corcept Therapeutics, Inc. has a beta of 0.247, which suggesting that the stock is 75.347% less volatile than S&P 500. In comparison Amneal Pharmaceuticals, Inc. has a beta of 1.356, suggesting its more volatile than the S&P 500 by 35.638%.
-
Which is a Better Dividend Stock CORT or AMRX?
Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amneal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Amneal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORT or AMRX?
Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than Amneal Pharmaceuticals, Inc. quarterly revenues of $784.5M. Corcept Therapeutics, Inc.'s net income of $19.4M is higher than Amneal Pharmaceuticals, Inc.'s net income of $18.1M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 39.12x while Amneal Pharmaceuticals, Inc.'s PE ratio is 1,035.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 5.52x versus 1.59x for Amneal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORTCorcept Therapeutics, Inc.5.52x 39.12x $207.6M $19.4M AMRXAmneal Pharmaceuticals, Inc.1.59x 1,035.46x $784.5M $18.1M
-
Which has Higher Returns CORT or AXSM?
Axsome Therapeutics, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of -27.62%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Axsome Therapeutics, Inc.'s return on equity of -327.97%.
Company Gross Margin Earnings Per Share Invested Capital CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M -
What do Analysts Say About CORT or AXSM?
Corcept Therapeutics, Inc. has a consensus price target of $84.00, signalling upside risk potential of 145.33%. On the other hand Axsome Therapeutics, Inc. has an analysts' consensus of $216.09 which suggests that it could grow by 16.07%. Given that Corcept Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CORTCorcept Therapeutics, Inc.3 1 1 AXSMAxsome Therapeutics, Inc.16 1 0 -
Is CORT or AXSM More Risky?
Corcept Therapeutics, Inc. has a beta of 0.247, which suggesting that the stock is 75.347% less volatile than S&P 500. In comparison Axsome Therapeutics, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.011%.
-
Which is a Better Dividend Stock CORT or AXSM?
Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Axsome Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORT or AXSM?
Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are larger than Axsome Therapeutics, Inc. quarterly revenues of $171M. Corcept Therapeutics, Inc.'s net income of $19.4M is higher than Axsome Therapeutics, Inc.'s net income of -$47.2M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 39.12x while Axsome Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 5.52x versus 16.33x for Axsome Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORTCorcept Therapeutics, Inc.5.52x 39.12x $207.6M $19.4M AXSMAxsome Therapeutics, Inc.16.33x -- $171M -$47.2M
-
Which has Higher Returns CORT or HROW?
Harrow, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 1.42%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Harrow, Inc.'s return on equity of -8.95%.
Company Gross Margin Earnings Per Share Invested Capital CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M HROWHarrow, Inc.75.28% $0.03 $298.5M -
What do Analysts Say About CORT or HROW?
Corcept Therapeutics, Inc. has a consensus price target of $84.00, signalling upside risk potential of 145.33%. On the other hand Harrow, Inc. has an analysts' consensus of $70.63 which suggests that it could grow by 38.97%. Given that Corcept Therapeutics, Inc. has higher upside potential than Harrow, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Harrow, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CORTCorcept Therapeutics, Inc.3 1 1 HROWHarrow, Inc.7 0 0 -
Is CORT or HROW More Risky?
Corcept Therapeutics, Inc. has a beta of 0.247, which suggesting that the stock is 75.347% less volatile than S&P 500. In comparison Harrow, Inc. has a beta of 0.073, suggesting its less volatile than the S&P 500 by 92.734%.
-
Which is a Better Dividend Stock CORT or HROW?
Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harrow, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Harrow, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORT or HROW?
Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are larger than Harrow, Inc. quarterly revenues of $71.6M. Corcept Therapeutics, Inc.'s net income of $19.4M is higher than Harrow, Inc.'s net income of $1M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 39.12x while Harrow, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 5.52x versus 7.59x for Harrow, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORTCorcept Therapeutics, Inc.5.52x 39.12x $207.6M $19.4M HROWHarrow, Inc.7.59x -- $71.6M $1M
-
Which has Higher Returns CORT or RARE?
Ultragenyx Pharmaceutical, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of -62.32%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Ultragenyx Pharmaceutical, Inc.'s return on equity of -558.7%.
Company Gross Margin Earnings Per Share Invested Capital CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M RAREUltragenyx Pharmaceutical, Inc.81.75% -$1.29 $1.2B -
What do Analysts Say About CORT or RARE?
Corcept Therapeutics, Inc. has a consensus price target of $84.00, signalling upside risk potential of 145.33%. On the other hand Ultragenyx Pharmaceutical, Inc. has an analysts' consensus of $56.55 which suggests that it could grow by 159.05%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Corcept Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CORTCorcept Therapeutics, Inc.3 1 1 RAREUltragenyx Pharmaceutical, Inc.15 1 0 -
Is CORT or RARE More Risky?
Corcept Therapeutics, Inc. has a beta of 0.247, which suggesting that the stock is 75.347% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical, Inc. has a beta of 0.161, suggesting its less volatile than the S&P 500 by 83.893%.
-
Which is a Better Dividend Stock CORT or RARE?
Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORT or RARE?
Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are larger than Ultragenyx Pharmaceutical, Inc. quarterly revenues of $207M. Corcept Therapeutics, Inc.'s net income of $19.4M is higher than Ultragenyx Pharmaceutical, Inc.'s net income of -$129M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 39.12x while Ultragenyx Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 5.52x versus 3.20x for Ultragenyx Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORTCorcept Therapeutics, Inc.5.52x 39.12x $207.6M $19.4M RAREUltragenyx Pharmaceutical, Inc.3.20x -- $207M -$129M
-
Which has Higher Returns CORT or UTHR?
United Therapeutics Corp. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 42.36%. Corcept Therapeutics, Inc.'s return on equity of 16% beat United Therapeutics Corp.'s return on equity of 19.2%.
Company Gross Margin Earnings Per Share Invested Capital CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M UTHRUnited Therapeutics Corp.87.38% $7.16 $6.6B -
What do Analysts Say About CORT or UTHR?
Corcept Therapeutics, Inc. has a consensus price target of $84.00, signalling upside risk potential of 145.33%. On the other hand United Therapeutics Corp. has an analysts' consensus of $531.25 which suggests that it could grow by 11.6%. Given that Corcept Therapeutics, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Corcept Therapeutics, Inc. is more attractive than United Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings CORTCorcept Therapeutics, Inc.3 1 1 UTHRUnited Therapeutics Corp.8 5 0 -
Is CORT or UTHR More Risky?
Corcept Therapeutics, Inc. has a beta of 0.247, which suggesting that the stock is 75.347% less volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.572%.
-
Which is a Better Dividend Stock CORT or UTHR?
Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORT or UTHR?
Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than United Therapeutics Corp. quarterly revenues of $799.5M. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 39.12x while United Therapeutics Corp.'s PE ratio is 18.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 5.52x versus 7.34x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORTCorcept Therapeutics, Inc.5.52x 39.12x $207.6M $19.4M UTHRUnited Therapeutics Corp.7.34x 18.04x $799.5M $338.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 21.87% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 16.79% over the past day.
